scholarly journals OC09.03: A carotid ultrasound study of the effectiveness of hormone therapy in preventing arteriosclerosis in women with premature ovarian failure and in menopausal women

2013 ◽  
Vol 42 (s1) ◽  
pp. 17-17
Author(s):  
S. Igarashi ◽  
T. Nako ◽  
J. Kakogawa ◽  
A. Tozawa ◽  
B. Ishizuka ◽  
...  
2010 ◽  
Vol 128 (4) ◽  
pp. 211-214 ◽  
Author(s):  
Patrícia Magda Soares ◽  
César Cabello ◽  
Luis Alberto Magna ◽  
Eduardo Tinois ◽  
Cristina Laguna Benetti-Pinto

CONTEXT AND OBJECTIVE: Studies on postmenopausal women have reported increased risk of breast cancer relating to the type and duration of hormone therapy (HT) used. Women with premature ovarian failure (POF) represent a challenge, since they require prolonged HT. Little is known about the impact of prolonged HT use on these women's breasts. This study aimed to evaluate the effects of one type of HT on the breast density of women with POF, compared with postmenopausal women. DESIGN AND SETTING: Cross-sectional study at the Department of Obstetrics and Gynecology, Universidade Estadual de Campinas (Unicamp). METHODS: 31 women with POF and 31 postmenopausal women, all using HT consisting of conjugated equine estrogen combined with medroxyprogesterone acetate, and matched according to HT duration, were studied. Mammography was performed on all subjects and was analyzed by means of digitization or Wolfe's classification, stratified into two categories: non-dense (N1 and P1 patterns) and dense (P2 and Dy). RESULTS: No significant difference in breast density was found between the two groups through digitization or Wolfe's classification. From digitization, the mean breast density was 24.1% ± 14.6 and 18.1% ± 17.2 in the POF and postmenopausal groups, respectively (P = 0.15). Wolfe's classification identified dense breasts in 51.6% and 29.0%, respectively (P = 0.171). CONCLUSION: There was no difference in breast density between the women with POF and postmenopausal women, who had used HT for the same length of time. These results may help towards compliance with HT use among women with POF.


2004 ◽  
Vol 89 (8) ◽  
pp. 3907-3913 ◽  
Author(s):  
Sophia N. Kalantaridou ◽  
Katerina K. Naka ◽  
Evangelos Papanikolaou ◽  
Nicolaos Kazakos ◽  
Maria Kravariti ◽  
...  

Author(s):  
Tarek A Gelbaya ◽  
Srisailesh Vitthala ◽  
Luciano G Nardo ◽  
Cindy Farquhar ◽  
Mourad MW Seif

2020 ◽  
Vol 273 ◽  
pp. 562-566
Author(s):  
Camila Menezes ◽  
Gabriela Rezende Pravata ◽  
Daniela Angerame Yela ◽  
Cristina Laguna Benetti-Pinto

1991 ◽  
Vol 3 (5) ◽  
pp. 537 ◽  
Author(s):  
R Kirsop ◽  
CR Brock ◽  
BG Robinson ◽  
RJ Baber ◽  
JV Wells ◽  
...  

The sera of 30 patients with premature ovarian failure (POF) and a control group of 19 menopausal women were screened for anti-ovarian and other tissue antibodies. Anti-ovarian antibodies were detected by indirect immunofluorescence using monkey ovary substrates from two different commercial sources. Serum anti-ovarian antibodies were detected in only one of the patients with POF. This test does not appear to be reliable for the detection of serum anti-ovarian antibodies, and the clinical usefulness of screening patients with POF for anti-ovarian antibodies is questionable.


Sign in / Sign up

Export Citation Format

Share Document